- ►annals.org [PDF] JE Calfee - Annals of Internal Medicine, 2001 - Am Coll Physicians Price controls could have a substantial negative effect on pharma- ceutical
research and development. Extensive research is required before the development
costs of a new drug or its benefits are known; most new drug development ... Cited by 24 - Related articles - All 5 versions
- ►annals.org [PDF] F Davidoff - Annals of Internal Medicine, 2002 - Am Coll Physicians TO THE EDITOR: Dr. Davidoff's appeal to the kind hearts of the pharmaceutical
industry to restrict drug pricing (1) is fatally flawed. First, the captains of
the drug industry have a fiduciary duty to their stockholders. Unlike ... Cited by 26 - Related articles - All 2 versions
- ►adisonline.com [PDF] JE Calfee - Pharmacoeconomics, 2000 - ingentaconnect.com Abstract In most markets, research and development are driven by expected
prices, and those prices are determined mainly by consumer willingness to pay
for the po- tential benefits of new products. In the pharmaceutical market, ... Cited by 12 - Related articles - BL Direct - All 5 versions
- ►nih.gov [PDF] F Fleck - BMJ: British Medical Journal, 2003 - pubmedcentral.nih.gov WTO's rules on patents so that drugs such as antiretrovirals for combating HIV
infection and AIDS could be produced to meet urgent public health needs in the
world's poorer countries. Developing countries accused the United States of ... Cited by 4 - Related articles - All 9 versions
A Blomqvist, J Xu - Health Policy Working Paper Series, 2001 - hc-sc.gc.ca Secondary page of September 2001 Health Canada Working Paper.
Cited by 6 - Related articles - Cached - All 2 versions
MBA Tim Schwermann, W Greiner, JMG vd … - Value in Health - ispor.org Address correspondence to: JM Graf vd Schulenburg, Universitat Hannover,
Institut fuer Versicherungsbetrie- bslehre Forschungsstelle fuer
Gesundheitsokonomie und Gesundheitssystemforschung, Konigsworther Platz 1, ... Cited by 8 - Related articles - View as HTML - BL Direct - All 4 versions
J Darbà - The European Journal of Health Economics, 2003 - Springer The Spanish pharmaceutical market was the seventh largest in the world in 1999
and was valued at € 9.799 million. Per head spending was calculated at€
246.62. The pharmaceutical market made up more than 23% of Spanish ... Cited by 9 - Related articles - All 3 versions
[CITATION] Timely access to generic drugs: issues for health policy in Canada
- ►pharm.or.jp [PDF] S BURAPADAJA， 川崎直人, O … - Yakugaku zasshi, 2007 - J-STAGE Page 1. hon p.1 [100%] 515 e-mail: kawasaki＠phar.kindai.ac.jp 515 YAKUGAKU ZASSHI
127(3) 515―526 (2007) 2007 The Pharmaceutical Society of Japan ... Cited by 1 - Related articles - BL Direct - All 5 versions
